Literature DB >> 30084841

PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection.

Loghman Salimzadeh1,2,3, Nina Le Bert1, Charles-A Dutertre1,2, Upkar S Gill4, Evan W Newell2, Christian Frey5, Magdeleine Hung5, Nikolai Novikov5, Simon Fletcher5, Patrick Tf Kennedy4, Antonio Bertoletti1,2.   

Abstract

Chronic HBV (CHB) infection suppresses virus-specific T cells, but its impact on humoral immunity has been poorly analyzed. Here, we developed a dual-staining method that utilizes hepatitis B virus (HBV) surface antigens (HBsAg) labeled with fluorochromes as "baits" for specific ex vivo detection of HBsAg-specific B cells and analysis of their quantity, function, and phenotype. We studied healthy vaccinated subjects (n = 18) and patients with resolved (n = 21), acute (n = 11), or chronic (n = 96) HBV infection and observed that frequencies of circulating HBsAg-specific B cells were independent of HBV infection status. In contrast, the presence of serum HBsAg affected function and phenotype of HBsAg-specific B cells that were unable to mature in vitro into Ab-secreting cells and displayed an increased expression of markers linked to hyperactivation (CD21lo) and exhaustion (PD-1). Importantly, B cell alterations were not limited to HBsAg-specific B cells, but affected the global B cell population. HBsAg-specific B cell maturation could be partially restored by a method involving the combination of the cytokines IL-2 and IL-21 and CD40L-expressing feeder cells and was further boosted by the addition of anti-PD-1 Abs. In conclusion, HBV infection has a marked impact on global and HBV-specific humoral immunity, yet HBsAg-specific B cells are amenable to a partial rescue by B cell-maturing cytokines and PD-1 blockade.

Entities:  

Keywords:  B cells; Hepatitis; Hepatology; Infectious disease

Mesh:

Substances:

Year:  2018        PMID: 30084841      PMCID: PMC6159957          DOI: 10.1172/JCI121957

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection.

Authors:  W O Böcher; S Herzog-Hauff; W Herr; K Heermann; G Gerken; K H Meyer Zum Büschenfelde; H F Löhr
Journal:  Clin Exp Immunol       Date:  1996-07       Impact factor: 4.330

2.  PD-1 is a novel regulator of human B-cell activation.

Authors:  Marie-Laure Thibult; Emilie Mamessier; Julie Gertner-Dardenne; Sonia Pastor; Sylvaine Just-Landi; Luc Xerri; Bruno Chetaille; Daniel Olive
Journal:  Int Immunol       Date:  2012-10-18       Impact factor: 4.823

3.  Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.

Authors:  Bertram Bengsch; Bianca Martin; Robert Thimme
Journal:  J Hepatol       Date:  2014-07-10       Impact factor: 25.083

4.  Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients.

Authors:  V Barnaba; G Valesini; M Levrero; C Zaccari; A Van Dyke; M Falco; A Musca; F Balsano
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

5.  Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection.

Authors:  M K Maini; C Boni; G S Ogg; A S King; S Reignat; C K Lee; J R Larrubia; G J Webster; A J McMichael; C Ferrari; R Williams; D Vergani; A Bertoletti
Journal:  Gastroenterology       Date:  1999-12       Impact factor: 22.682

6.  Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen.

Authors:  Tian-Ying Zhang; Quan Yuan; Jing-Hua Zhao; Ya-Li Zhang; Lun-Zhi Yuan; Ying Lan; Yu-Chieh Lo; Cheng-Pu Sun; Chang-Ru Wu; Jun-Fang Zhang; Ying Zhang; Jia-Li Cao; Xue-Ran Guo; Xuan Liu; Xiao-Bing Mo; Wen-Xin Luo; Tong Cheng; Yi-Xin Chen; Mi-Hua Tao; James Wk Shih; Qin-Jian Zhao; Jun Zhang; Pei-Jer Chen; Y Adam Yuan; Ning-Shao Xia
Journal:  Gut       Date:  2015-09-30       Impact factor: 23.059

7.  Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro.

Authors:  Gustaf E Rydell; Kasthuri Prakash; Heléne Norder; Magnus Lindh
Journal:  Virology       Date:  2017-06-10       Impact factor: 3.616

Review 8.  Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.

Authors:  Sonali Paul; Aaron Dickstein; Akriti Saxena; Norma Terrin; Kathleen Viveiros; Ethan M Balk; John B Wong
Journal:  Hepatology       Date:  2017-06-22       Impact factor: 17.425

9.  Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus.

Authors:  Scott M Ward; Prabhjeet Phalora; Daniel Bradshaw; Heike Leyendeckers; Paul Klenerman
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

Review 10.  Viral subversion of B cell responses within secondary lymphoid organs.

Authors:  Mirela Kuka; Matteo Iannacone
Journal:  Nat Rev Immunol       Date:  2017-12-18       Impact factor: 53.106

View more
  75 in total

Review 1.  Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad.

Authors:  Marc G Ghany; Jordan J Feld; Kyong-Mi Chang; Henry L Y Chan; Anna S F Lok; Kumar Visvanathan; Harry L A Janssen
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-02-10

Review 2.  Checkpoint Molecules in Rheumatology-or the Benefits of Being Exhausted.

Authors:  Stinne Ravn Greisen; Bent Deleuran
Journal:  Curr Rheumatol Rep       Date:  2021-03-02       Impact factor: 4.592

3.  Chronic hepatitis B: the demise of the 'inactive carrier' phase.

Authors:  Apostolos Koffas; Manoj Kumar; Upkar S Gill; Ankur Jindal; Patrick T F Kennedy; S K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

4.  A putative amphipathic alpha helix in hepatitis B virus small envelope protein plays a critical role in the morphogenesis of subviral particles.

Authors:  Sisi Yang; Zhongliang Shen; Yaoyue Kang; Liren Sun; Usha Viswanathan; Hongying Guo; Tianlun Zhou; Xinghong Dai; Jinhong Chang; Jiming Zhang; Ju-Tao Guo
Journal:  J Virol       Date:  2021-02-03       Impact factor: 5.103

Review 5.  Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting.

Authors:  Arjuna Singanayagam; Evangelos Triantafyllou
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

6.  OMIP-068: High-Dimensional Characterization of Global and Antigen-Specific B Cells in Chronic Infection.

Authors:  Katherine Cascino; Mario Roederer; Thomas Liechti
Journal:  Cytometry A       Date:  2020-08-28       Impact factor: 4.355

7.  Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients.

Authors:  Sachiyo Yoshio; Yohei Mano; Hiroyoshi Doi; Hirotaka Shoji; Tomonari Shimagaki; Yuzuru Sakamoto; Hironari Kawai; Michitaka Matsuda; Taizo Mori; Yosuke Osawa; Masaaki Korenaga; Masaya Sugiyama; Masashi Mizokami; Eiji Mita; Keiko Katayama; Junko Tanaka; Tatsuya Kanto
Journal:  JCI Insight       Date:  2018-10-18

8.  Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model.

Authors:  Masatoshi Kakizaki; Yuichiro Yamamoto; Motoyuki Otsuka; Kouichi Kitamura; Masatoshi Ito; Hideki Derek Kawai; Masamichi Muramatsu; Tatehiro Kagawa; Ai Kotani
Journal:  J Biol Chem       Date:  2020-07-10       Impact factor: 5.157

9.  Entering the spotlight: hepatitis B surface antigen-specific B cells.

Authors:  Christoph Neumann-Haefelin; Robert Thimme
Journal:  J Clin Invest       Date:  2018-09-17       Impact factor: 14.808

Review 10.  Immunobiology and pathogenesis of hepatitis B virus infection.

Authors:  Matteo Iannacone; Luca G Guidotti
Journal:  Nat Rev Immunol       Date:  2021-05-17       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.